Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 110

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 110
---
daq could
adversely affect the trading market for our securities, as price quotations may not be as readily obtainable, which would likely have
a material adverse effect on the market price of our securities and the Company’s ability to raise additional capital.

Moreover, we can provide no assurance that trading
in our securities will continue over the counter or otherwise. As a result of the delisting, we could face significant material adverse
consequences, including:

| ● | a limited availability of market quotations for our securities; |

| ● | reduced liquidity with respect to our securities; |

<div align='center'>45</div>

| ● | a determination that our shares of common stock are “penny                                                                     
 stock”, which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting 
 in a reduced level of trading activity in the secondary trading market for our shares of common stock;                         |

| ● | a limited amount of news and analyst coverage for our company; 
 and                                                            |

| ● | a decreased ability to issue additional securities or obtain                                                                                  
 additional financing, including pursuant to the Fifth Securities Purchase Agreement, the July 2025 Keystone Purchase Agreement, or otherwise, 
 in the future.                                                                                                                                |

The National Securities
Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities,
which are referred to as “covered securities.” Because they have been delisted, our securities would not be covered securities
and we would be subject to regulation in each state in which we offer our securities. This state level regulation introduces additional
compliance requirements for brokers to consider making markets in our securities and will further negatively impact any trading liquidity
in our securities.

We may pursue orphan drug designation for certain of our product candidates, and we may not be able to obtain such designation, or obtain or maintain the benefits of such designation including orphan drug exclusivity, and even if we do, that exclusivity may not prevent regulatory authorities from approving other competing products.

In June 2025, the FDA granted
orphan drug designation to CER-1236 for the treatment of AML. We may seek orphan designation for additional product candidates in the
future; however, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug
if it is a drug or biologic intended to treat a rare disease or condition, defined as a patient population of fewer